3 research outputs found
Butik Citranggun Sdn. Bhd. / Nur Azwa Ibrahim ... [et al.]
Butik Citra Anggun Sdn. Bhd is set up with its main activity to provide tailoring
service to the customers. This business is fit in our environment as the tailoring industry
is always expanded. People need cloth in their daily life. They will ask for a tailor to
make specified sized clothes, especially for special occasions or events. In addition, the
world of fashion is always changing, and therefore both men and women will seek for a
new fashion.
Butik Citra Anggun will be located at No 28 Jalan Tiga Belas, Pusat Bandar
Puchong, Selangor. Our premise is at the centre of Puchong town. It is near TESCO
Hypermarket, IOI Mall and Giant Hypermarket and also surrounded by many residential
areas. Moreover we sure this is strategic place to our business as there are not many
tailoring service that are set up commercially.
We choose the tailoring service because the industry will never fade away by time
and there will always demand for it. Although there is a big market and supply for ready
made clothes, the tastes and preferences for everybody is different. With the existence of
Butik Citra Anggun, our customers can fulfill their needs and wants by subscribing our
tailoring service. Besides, we also provide ready made traditional clothes which are sew
by our tailors as the additional choice for the customers. Our target market is the
employed woman of Pusat Bandar Puchong
Butik CitrAnggun / Nur Azwa Ibrahim ⊠[et al.]
Butik Citra Anggun Sdn. Bhd is set up with its main activity to provide tailoring service to the customers. This business is fit in our environment as the tailoring industry is always expanded. People need cloth in their daily life. They will ask for a tailor to make specified sized clothes, especially for special occasions or events. In addition, the world of fashion is always changing, and therefore both men and women will seek for a new fashion. Butik Citra Anggun will be located at No 28 Jalan Tiga Belas, Pusat Bandar Puchong, Selangor. Our premise is at the centre of Puchong town. It is near TESCO Hypermarket, IOI Mall and Giant Hypermarket and also surrounded by many residential areas. Moreover we sure this is strategic place to our business as there are not many tailoring service that are set up commercially. We choose the tailoring service because the industry will never fade away by time and there will always demand for it. Although there is a big market and supply for ready made clothes, the tastes and preferences for everybody is different. With the existence of Butik Citra Anggun, our customers can fulfill their needs and wants by subscribing our tailoring service. Besides, we also provide ready made traditional clothes which are sew by our tailors as the additional choice for the customers. Our target market is the employed woman of Pusat Bandar Puchong. Butik Citra Anggun Sdn. Bhd will start its operation on January 2006. We are looking forward to expand our business. We also hope that Butik Citra Anggun Sdn. Bhd. can survive longer, making more profit and produce good quality of services to our customers
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis
IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm.
OBJECTIVE To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.
DATA SOURCES Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts.
STUDY SELECTION Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria.
DATA EXTRACTION AND SYNTHESIS In this prospectivemeta-analysis, risk of biaswas assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality.
MAIN OUTCOMES AND MEASURES The primary outcome measurewas all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days.
RESULTS A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P =.003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P <.001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P =.52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16).
CONCLUSIONS AND RELEVANCE In this prospectivemeta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality